Study of a Mouse Tumor Cell Line Resistant to Verapamil
Author Information
Author(s): P.R. Twentyman, K.A. Wright, N.E. Fox
Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit
Hypothesis
What mechanisms lead to resistance against the drug verapamil in a mouse tumor cell line?
Conclusion
The study found that the EMT6/VRP cell line is resistant to verapamil through a different mechanism than other drugs like adriamycin.
Supporting Evidence
- The EMT6/VRP cells showed a 4-fold resistance to verapamil compared to the parent line.
- After removal of verapamil, the EMT6/VRP cells reverted to normal size and morphology within 3 days.
- EMT6/VRP cells accumulated more 3H-VRP than the parent line, indicating altered drug handling.
- The resistance mechanism in EMT6/VRP is distinct from that of multidrug resistant cell lines.
Takeaway
Scientists created a special mouse cancer cell line that can survive a drug called verapamil, and they learned it doesn't work the same way as other cancer drugs.
Methodology
The study involved creating a VRP-resistant subline from the EMT6 mouse tumor cell line by gradually increasing the concentration of verapamil in the growth medium.
Limitations
The study does not explore the sensitivity of the EMT6/VRP cells to daunorubicin cytotoxicity.
Statistical Information
P-Value
0.006
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website